Outcome of MPN after MDS/AML transformation in literature series
| Study . | Sample size . | Treatment . | CR/CRi, % . | Median survival with specific treatment, mo . | Overall median survival, mo . |
|---|---|---|---|---|---|
| Cervantes et al, 199124 | 13 | Not detailed | 3.0 | ||
| Passamonti, 20055 | 23 | Best supportive care (n = 7) | 2.5 | 2.9 | |
| Low dose Ara-C (n = 4) | |||||
| 6-Thioguanine (n = 4) | |||||
| Intensive chemotherapy(n = 8) | 13 | 5.6 | |||
| Mesa et al, 200525 | 91 | Best supportive care (n = 48) | 2.0 | 2.6 | |
| Oral busulfan/etoposide (n = 4) | 0 | 2.9 | |||
| Vindesine (n = 9) | |||||
| Other (n = 6) | |||||
| Intensive chemotherapy (n = 24) | 0 | 3.9 | |||
| Tam et al, 200826 | 74 | Best supportive care (n = 19) | 5.0 | ||
| Gemtuzumab (n = 4) | 0 | 6.0 | |||
| Azacytidine (n = 3) | |||||
| Dasatinib (n = 2) | |||||
| Other (n = 3) | |||||
| Intensive chemotherapy (n = 41) | 46 | 7.0 |
| Study . | Sample size . | Treatment . | CR/CRi, % . | Median survival with specific treatment, mo . | Overall median survival, mo . |
|---|---|---|---|---|---|
| Cervantes et al, 199124 | 13 | Not detailed | 3.0 | ||
| Passamonti, 20055 | 23 | Best supportive care (n = 7) | 2.5 | 2.9 | |
| Low dose Ara-C (n = 4) | |||||
| 6-Thioguanine (n = 4) | |||||
| Intensive chemotherapy(n = 8) | 13 | 5.6 | |||
| Mesa et al, 200525 | 91 | Best supportive care (n = 48) | 2.0 | 2.6 | |
| Oral busulfan/etoposide (n = 4) | 0 | 2.9 | |||
| Vindesine (n = 9) | |||||
| Other (n = 6) | |||||
| Intensive chemotherapy (n = 24) | 0 | 3.9 | |||
| Tam et al, 200826 | 74 | Best supportive care (n = 19) | 5.0 | ||
| Gemtuzumab (n = 4) | 0 | 6.0 | |||
| Azacytidine (n = 3) | |||||
| Dasatinib (n = 2) | |||||
| Other (n = 3) | |||||
| Intensive chemotherapy (n = 41) | 46 | 7.0 |
A total of 201 patients were evaluated.
MPN indicates myeloproliferative neoplasm; AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; CR, complete response; CRi, complete response with incomplete recovery of cytopenias; and Ara-C, cytosine arabinoside.